15 years of historical data (2010–2024) · Healthcare · Drug Manufacturers - General
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
AbbVie Inc. trades at 97.1x earnings, 125% above its 5-year average of 43.2x, sitting at the 100th percentile of its historical range. Compared to the Healthcare sector median P/E of 23.7x, the stock trades at a premium of 310%. On a free-cash-flow basis, the stock trades at 23.0x P/FCF, 81% above the 5-year average of 12.7x.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $410.1B | $315.1B | $274.8B | $287.3B | $240.6B | $179.3B | $131.4B | $142.5B | $155.0B | $102.1B | $97.0B |
| Enterprise Value | $472.4B | $377.4B | $322.1B | $342.3B | $308.4B | $257.9B | $158.6B | $175.5B | $183.1B | $133.9B | $120.2B |
| P/E Ratio → | 97.08 | 74.35 | 56.97 | 24.38 | 20.99 | 39.39 | 16.77 | 25.05 | 29.31 | 17.25 | 18.93 |
| P/S Ratio | 7.28 | 5.59 | 5.06 | 4.95 | 4.28 | 3.91 | 3.95 | 4.35 | 5.49 | 3.98 | 4.24 |
| P/B Ratio | 122.29 | 93.66 | 26.43 | 16.62 | 15.59 | 13.69 | — | — | 30.42 | 22.03 | 24.58 |
| P/FCF | 23.00 | 17.67 | 12.45 | 11.85 | 10.94 | 10.68 | 10.29 | 11.14 | 16.44 | 15.56 | 13.85 |
| P/OCF | 21.81 | 16.75 | 12.03 | 11.52 | 10.56 | 10.19 | 9.86 | 10.61 | 15.56 | 14.51 | 12.87 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
AbbVie Inc.'s enterprise value stands at 27.0x EBITDA, 78% above its 5-year average of 15.1x. The Healthcare sector median is 13.8x, placing the stock at a 95% premium on an enterprise-value basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 6.70 | 5.93 | 5.90 | 5.49 | 5.63 | 4.77 | 5.36 | 6.49 | 5.22 | 5.26 |
| EV / EBITDA | 26.96 | 21.54 | 15.01 | 12.88 | 11.66 | 14.46 | 10.57 | 21.54 | 16.58 | 12.71 | 14.36 |
| EV / EBIT | 51.70 | 57.84 | 38.01 | 21.79 | 20.01 | 44.07 | 15.53 | 26.82 | 20.63 | 14.99 | 16.33 |
| EV / FCF | — | 21.16 | 14.60 | 14.12 | 14.03 | 15.36 | 12.41 | 13.73 | 19.41 | 20.40 | 17.17 |
Margins and return-on-capital ratios measuring operating efficiency
AbbVie Inc. earns an operating margin of 16.2%. Operating margins have compressed from 31.2% to 16.2% over the past 3 years, signaling potential cost pressures or competitive headwinds. Return on equity of 62.2% is exceptionally high. ROIC of 11.1% represents solid returns on invested capital.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 70.0% | 70.0% | 62.4% | 70.0% | 69.0% | 66.4% | 77.6% | 76.4% | 75.0% | 77.2% | 80.3% |
| Operating Margin | 16.2% | 16.2% | 23.5% | 31.2% | 31.9% | 24.8% | 39.0% | 19.5% | 33.8% | 36.4% | 33.0% |
| Net Profit Margin | 7.6% | 7.6% | 9.0% | 20.4% | 20.5% | 10.1% | 23.7% | 17.4% | 18.8% | 23.2% | 22.5% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 62.2% | 62.2% | 35.1% | 72.3% | 80.9% | 187.5% | — | — | 109.1% | 138.7% | 180.9% |
| ROA | 3.2% | 3.2% | 3.6% | 8.3% | 7.8% | 3.9% | 10.6% | 8.7% | 7.8% | 10.0% | 12.8% |
| ROIC | 11.1% | 11.1% | 14.7% | 17.5% | 15.4% | 15.4% | 44.7% | 16.6% | 20.6% | 22.0% | 31.7% |
| ROCE | 9.5% | 9.5% | 12.4% | 16.4% | 15.4% | 11.6% | 22.5% | 13.3% | 17.3% | 19.0% | 25.9% |
Solvency and debt-coverage ratios — lower is generally safer
AbbVie Inc. carries a Debt/EBITDA ratio of 3.9x, which is moderately leveraged (24% above the sector average of 3.1x). Net debt stands at $62.3B ($67.8B total debt minus $5.5B cash). Interest coverage of 3.3x is adequate, though a cyclical earnings downturn could tighten the margin of safety.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 20.17 | 20.17 | 5.78 | 3.71 | 5.03 | 6.65 | — | — | 7.33 | 7.95 | 8.03 |
| Debt / EBITDA | 3.87 | 3.87 | 2.80 | 2.41 | 2.93 | 4.88 | 4.47 | 4.95 | 3.38 | 3.50 | 3.78 |
| Net Debt / Equity | — | 18.52 | 4.55 | 3.18 | 4.39 | 6.00 | — | — | 5.51 | 6.85 | 5.90 |
| Net Debt / EBITDA | 3.56 | 3.56 | 2.20 | 2.07 | 2.56 | 4.41 | 1.81 | 4.05 | 2.54 | 3.01 | 2.78 |
| Debt / FCF | — | 3.49 | 2.14 | 2.27 | 3.08 | 4.68 | 2.13 | 2.58 | 2.98 | 4.84 | 3.32 |
| Interest Coverage | 3.25 | 3.25 | 5.74 | 8.12 | 7.40 | 4.63 | 7.28 | 4.74 | 8.30 | 8.92 | 10.48 |
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.66x is below 1.0, meaning current liabilities exceed current assets — though the company's $5.5B cash position helps mitigate short-term liquidity concerns. The current ratio has declined from 0.96x to 0.66x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.66 | 0.66 | 0.87 | 0.96 | 0.79 | 0.84 | 3.18 | 0.98 | 1.28 | 1.65 | 1.50 |
| Quick Ratio | 0.55 | 0.55 | 0.76 | 0.84 | 0.70 | 0.73 | 3.06 | 0.89 | 1.18 | 1.51 | 1.34 |
| Cash Ratio | 0.14 | 0.14 | 0.34 | 0.31 | 0.28 | 0.30 | 2.56 | 0.47 | 0.59 | 0.66 | 0.77 |
| Asset Turnover | — | 0.42 | 0.40 | 0.42 | 0.38 | 0.30 | 0.37 | 0.55 | 0.40 | 0.39 | 0.43 |
| Inventory Turnover | 4.04 | 4.04 | 4.98 | 4.87 | 5.58 | 4.65 | 4.10 | 4.81 | 4.39 | 4.04 | 2.62 |
| Days Sales Outstanding | — | 70.75 | 74.96 | 70.76 | 64.80 | 70.30 | 59.56 | 60.00 | 65.82 | 67.74 | 75.53 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
AbbVie Inc. returns 3.1% to shareholders annually — split between a 2.7% dividend yield and 0.4% buyback yield. The payout ratio exceeds 100% at 257.7%, meaning the company is paying out more than it earns — this level is unsustainable long-term without earnings recovery. The earnings yield of 1.0% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 2.7% | 3.5% | 3.8% | 3.5% | 3.8% | 4.3% | 4.8% | 3.9% | 2.6% | 3.6% | 3.4% |
| Payout Ratio | 257.7% | 257.7% | 216.7% | 84.9% | 80.2% | 167.2% | 80.8% | 98.1% | 77.4% | 62.4% | 64.0% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 1.0% | 1.3% | 1.8% | 4.1% | 4.8% | 2.5% | 6.0% | 4.0% | 3.4% | 5.8% | 5.3% |
| FCF Yield | 4.3% | 5.7% | 8.0% | 8.4% | 9.1% | 9.4% | 9.7% | 9.0% | 6.1% | 6.4% | 7.2% |
| Buyback Yield | 0.4% | 0.5% | 0.7% | 0.5% | 0.4% | 0.5% | 0.5% | 8.4% | 0.9% | 5.9% | 7.8% |
| Total Shareholder Yield | 3.1% | 4.0% | 4.6% | 4.0% | 4.2% | 4.8% | 5.3% | 12.3% | 3.6% | 9.5% | 11.2% |
| Shares Outstanding | — | $1.8B | $1.8B | $1.8B | $1.8B | $1.7B | $1.5B | $1.5B | $1.6B | $1.6B | $1.6B |
Compare ABBV with 5 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| ABBVYou | $410B | 97.1 | 27.0 | 23.0 | 70.0% | 16.2% | 62.2% | 11.1% | 3.9 |
| AMGN | $209B | 27.3 | 12.6 | 25.8 | 82.5% | 40.5% | 106.1% | 20.7% | 2.7 |
| GILD | $186B | 392.0 | 45.7 | 18.0 | 78.3% | 5.8% | 2.3% | 3.2% | 6.0 |
| NVO | $126B | 10.3 | 6.3 | 14.1 | 81.0% | 41.4% | 58.4% | 34.9% | 0.9 |
| BIIB | $28B | 21.7 | 11.4 | 13.7 | 70.5% | 19.1% | 7.4% | 6.5% | 2.5 |
| SCLX | $2B | -0.4 | — | 77.8 | 70.5% | -147.4% | — | — | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 15 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how ABBV stacks up against sector leader Amgen Inc..
Start ComparisonAbbVie Inc.'s current P/E ratio is 97.1x. The historical average is 31.8x. This places it at the 100th percentile of its historical range.
AbbVie Inc.'s current EV/EBITDA is 27.0x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 15.4x.
AbbVie Inc.'s return on equity (ROE) is 62.2%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 88.4%.
Based on historical data, AbbVie Inc. is trading at a P/E of 97.1x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
AbbVie Inc.'s current dividend yield is 2.68% with a payout ratio of 257.7%.
AbbVie Inc. has 70.0% gross margin and 16.2% operating margin. Operating margin between 10-20% is typical for established companies.
AbbVie Inc.'s Debt/EBITDA ratio is 3.9x, indicating high leverage. A ratio between 2-4x is manageable but warrants monitoring.